39 results about "PULMONARY CARCINOMA" patented technology

The present invention is concerned with a novel antigens associated with human tumors, including carcinomas of the colon or lung, as well as novel monoclonal antibodies which specifically bind to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antigens include 100 kDa glycoprotein that has a colorectal cancer membrane bound and a soluble form, has a UV absorbance peak at about 228 nm, an isoelectric point of about 3.5 to 4, a sialic acid content of about 20%, and does not substantially bind to an antibody specific for ACT. The antibodies find use both in methods such as the detection of malignant cells associated with tumors and in monitoring therapeutic treatment of humans with tumors.

The invention discloses tetrahydropalmatine derivatives and a preparation method and application thereof. The structural formula of the tetrahydropalmatine derivatives is shown as a formula II, wherein R is octyl, isopropyl or 3-methybutyl. The provided application is the application of the tetrahydropalmatine derivatives shown as the formula II or pharmaceutically acceptable salts thereof in the preparation of eukaryotic tumor cell antiblastics and medicaments for preventing and/or treating tumors. The results of in-vitro anti-tumor activity experiments prove that each tetrahydropalmatine derivative has the effect of inhibiting human lung cancer cells A-549, KB human nasopharyngeal carcinoma cells, and HL-60 leukemia cell strains to a certain extent. The results show that the tetrahydropalmatine derivatives shown as the formula II can be applied to preparing the medicaments for treating the tumors, and the pharmaceutical application of the tetrahydropalmatine derivatives is widened.

The invention puts forward a universal cancer organoid in-vitro culture medium, which consists of a DMEM/F-12K (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12K) basic culture medium and an adding factor, wherein the adding factor consists of HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid), L-Glutamine, EGF (epidermal growth factor), Noggin, FGF (fibroblast growth factor)-10, A83-01 and Y27632. According to the culture medium of the embodiment of the invention, the success rate of organoid passage culture can be greatly improved, in addition, the universal culture of cancer samples, including gastric carcinoma, rectal carcinoma, lung carcinoma and the like, can be realized, culture cost is greatly lowered, the long-term culture of the organoid can be realized, and abiobank is established.

The invention provides 2-arylamine pyrimidine derivatives containing hydroxamic acid fragments shown in the formulas I and II. 2-arylamine pyrimidine containing carboxyl fragments is mainly used as a parent nucleus and is subjected to single-step condensation and related modification with hydroxylamine protected by THP to obtain a target compound. An experiment proves that the derivatives has the remarkable anti-proliferative effect on tumor cells (an overexpression EGFR human epidermal carcinoma cell line A431 and a human pulmonary carcinoma cell line H1975 resisting Gefitinib) related to EGFR tyrosine kinase activity on the cellular level, and tumor cells (a human cervical carcinoma cell line Hela, a human hepatoma cell line HepG2, a human promyelocytic acute leukemia cell line HL60, a human oral epidermoid carcinoma cell line KB, a human colon cancer cell line SW620) related to the HDAC histone acetylase activity, and the corresponding medicine for resisting cancer cells can be prepared. The general structural formula is shown in the description.

The invention relates to a 4-ring end substituted 2-1,2,3-triazole phenylamines compound, a preparation and a purpose, and concretely relates to the 4-ring end substituted 2-1,2,3-triazole phenylamines compound with a structure shown as a following general formula (I), the 4-ring end substituted 2-1,2,3-triazole phenylamines compound is a good tyrosinase inhibitor, and can better inhibit the viability and growth of lung carcinoma cells A549, H358, PC9 and HT-29, wherein R1 is selected from H and C1-4 alkyloxy; R2 is selected from a following structural unit:; and R3 is selected from a following structural unit:.

The invention relates to a traditional Chinese medicine with special anti-cancer effect for the treatment of adenocarcinoma classified by cytology, which is prepared by the traditional Chinese medicine raw materials with the weight percentage: 14 percent of ginseng, 13 percent of sanchi, 13 percent of prepared turtle shell, 1 percent of artificial musk, 13 percent of prepared turtle shell, 13 percent of adulterated pangolin scales, 15 percent of Chinese eaglewood, 13 percent of herba violae, 1 percent of gamboge and 4 percent of toad skin; the traditional Chinese medicine raw materials are ground into traditional Chinese medicine powder; the traditional Chinese medicine has the effects of strengthening body resistance, strengthening vital qi to eliminate pathogenic factor, nourishing yin, suppressing hyperactive yang, clearing heat, removing toxin, softening, resolving hard mass, activating blood circulation, removing blood stasis, enhancing human immunity, having vitality to kill cancer cells and having no evident toxicity to normal cells, thus being used for the treatment of adenocarcinoma, carcinoma of stomach, intestinal carcinoma, breast carcinoma, liver carcinoma and peripheral pulmonary carcinoma.

The invention relates to a Chinese preparation for treating lung carcinoma and process for preparation, wherein the constituents of the raw material include (by weight percent) prepared fleece-flower root 12-19%, notoginseng 4-9%, flitilarry bulb 5-8%, pericarpium trichosanthis 6-9%, peach kernel 4-9%, ground beetle 5-9%, red ginseng 6-9%, dyers woad leaf 7-15%, subprostrate sophora root 6-9%, poria cocos wolf 6-9%, lepidium seed 6-9%, dried orange peel 6-9%. The dose form of the medicament can be oral liquids, granules, capsules, powders, pills or tablets.

The present invention relates to a Chinese medicine composition for curing tumor and its preparation method. Said Chinese medicine composition is mainly made up by using the Chinese medicinal materials of biondia henryi and acanthopanax root and pharmaceutically-acceptable excipient through a certain preparation process. Said Chinese medicine composition can be made into oral capsule, table and oral liquor, and can be used for curing the disease of carcinoma of esophagus, carcinoma of stomach, liver-cancer, intestinal cancer and pulmonary carcinoma, etc.

The invention provides phthalimide compounds with an antiangiogenic activity, and the compound is as shown in a formula (I). According to the invention, the new phthalimide compounds 4,6-dihydroxyisoindol-1,3-dione and 4,6-dihydroxyisoindol-1-one isolated from traditional Chinese medicine peeled puffball fruiting body are subjected to a full synthesis and a derivative reaction at the same time, and seven new compounds are obtained. The compounds provided by the invention has no cytotoxic activity to human lung carcinoma A549 cells, can inhibit VEGF secretion level of the human lung carcinoma A549 cells, and thus can control growth of tumors through blocking or interfering signal transduction pathways of the VEGF/VEGFR. Pharmacological activity shows that the compound system provided by the invention is low in toxicity and high in security, and has important significance in inhibiting the growth of the tumors through an antiangiogenic mechanism.

The present invention relates to a medicine composition with the functions of clearing away heat, removing toxic material, removing dampness by diuresis, subduing swelling, removing blood stasis and stopping pain for effectively curing carcinoma of stomach, pulmonary carcinoma and carcinoma pancreas, etc. Its raw material composition includes (by wt%) 10-90% of Chinese gooseberry root and 10-90% of Chinese sage. Besides, said invention also provides its preparation method.

The present invention discloses a kit for detecting pulmonary carcinoma susceptibility. Said kit includes specific primer pair and specific fluorescent probe for detecting SNP site of position 161 in CYPIAI gene SEQ ID NO.1 and conventional component for making fluorescent quantitative PCR detection.

The present invention relates to taxane bromo-analogues with anticancer activity and preparation method thereof. It uses bromine and taxus crude extract containing cephalotmannine and 7-epi-10-deacetyl cephalotmannine to make addition reaction, then uses normal-phase preparation-type HPLC and reversed-phase semi-preparation HPLC to obtain two new taxane analogues: (2''R,3''S)-dibromo-7-epi-10-deacetyl cephalotmannine and (2''S,3''R)-dibromo-7-epi-10-deacetyl cephalotmannine. As compared with taxol said two analogues have similar and stronger anticancer activity for human mammary cancer cell (MCF-7), human pulmonary carcinoma cell (A549) and human oophoroma cell (A2780), and can be used for preparing anticancer medicine.

A method of treating a solid tumor in a mammal by inhibiting angiogenesis, including administering to the mammal which has a solid tumor selected from the group consisting of breast carcinoma, lung carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, neuroblastoma, central nervous system tumor, multiform glioblastoma and melanoma; a composition including brassinosteroids of general formula (I)

wherein can be a single or double bond and the configurations of carbon atoms C22 and C23 respectively linked to the substituents HO are S for both carbon atoms and a pharmaceutically acceptable additive.

The present disclosure is directed to a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a TiPARP agonist, wherein the TiPARP agonist may be, for example, a tamoxifen compound (e.g., tamoxifen or derivative thereof), flavone or derivative thereof, isoflavone or derivative thereof, diindolylmethane compound, or chlorinated dibenzo-p-dioxin (CDBD) compound or derivative thereof. The cancer may be associated with elevated expression of HIF-1α and may be selected from, for example, breast cancer, colon cancer, lung cancer, skin cancer, brain cancer, blood cancer, cervical cancer, liver cancer, prostate carcinoma, pancreas carcinoma, gastric carcinoma, ovarian carcinoma, renal cell carcinoma, mesothelioma, and melanoma. The cancer may, in some embodiments, exclude breast cancer.

The present invention discloses a kit for detecting pulmonary carcinoma susceptibility. Said kit includes specific primer pair and specific fluorescent probe for detecting SNP site of position 156 in ERCC2 gene SEQ ID NO.1 and conventional component for making fluorescent quantitative PCR detection.

The invention relates to a 2-1,2,3 triazole phenyl amines compound preparation method and an application, and concretely provides a 2-1,2,3 triazole phenyl amines compound with a structure shown as a general formula (I), the compound is a good tyrosinase inhibitor, and can better inhibit the survival and growth of lung carcinoma cells of A549, H358, PC9 and HT-29. R1 is selected from H and C1-4 alkyloxy; R2 is selected from the following structural units; and R3 is selected from the following structures.

The present invention discloses platinum (II) complexes with effective anticancer activity, characterized in that the new platinum (II) complexes are formed by reacting the anionic ligand of Camphoric radicals with the cationic ligand of amine platinum. The preparation process of these complexes and the in vitro inhibition effect of leukemic cell, oophoroma cell, hepatoma cell and pulmonary carcinoma cell with the typical compounds of the present invention are also disclosed. The structures of the present complexes are represented by the following formulas: (1), (2) and (3), wherein the Camphoric radicals in formula (l), (2) and (3) can be DL type raceme, D type optical isomer [1R, 3S) - (+) -Camphoric radical] or L type optical isomer [(1S, 3R)-(-)-Camphoric radical]. In formula (1) R is the same, representing hydrogen atom, C1-5alkyl or Cl-8oxaalkyl; In formula (2) the cyclohexanediamine is 1,2-t­rans-cyclohexanediamine, wherein both of the two chiral carbon atoms (marked with *) have the absolute configuration of R or S; In formula (3) R1 and R2 linked to the 4, 5-bis (aminomethyl) -2-alkyl-1, 3-­dioxolane, same or different, independently represent hydrogen atoms or C1-5 alkyl, or link to one carbon to form a cycle, wherein both of the two chiral carbon atoms(marked with *) have the absolute configuration of R or S. The platinum complexes of the present invention include all stereomers and mixtures of compounds represented by above formulas.

The present invention discloses a kit for detecting pulmonary carcinoma susceptibility. Said kit includes specific primer pair and specific fluorescent probe for detecting SNP site of position 156 in ERCC2 gene SEQ ID NO.1 and conventional component for making fluorescent quantitative PCR detection.